Investigational drug · Phase 3
HRS-5965
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
14
Any phase or sponsor naming "HRS-5965"
First trial start
2023
Dec 19, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-5965", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary IgA Nephropathy
- Paroxysmal Nocturnal Hemoglobinuria
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-5965" as an intervention, largest first.
- A Trial of HRS-5965 Capsule in Primary IgA NephropathyPivotal-lookingActive, not recruiting
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07014826 · 389 participants · Start Jun 4, 2025 · Primary completion Oct 2027
Drug: HRS-5965; Placebo · For: Primary IgA Nephropathy
Sites: Beijing, China
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07582133 · 380 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 2029
Drug: HRS-5965 Capsules · For: Primary IgA Nephropathy
Sites: Beijing, China
- Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruiting
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06238544 · 132 participants · Start Feb 6, 2024 · Primary completion Dec 2027
Drug: HRS-5965 tablets; HRS-5965 Capsules · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China; Tianjin, China
- A Trial of HRS-5965 Tablets in Primary IgA NephropathyPivotal-lookingCompleted
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06137768 · 123 participants · Start Dec 19, 2023 · Primary completion Oct 17, 2025
Drug: HRS-5965; Placebo · For: Primary IgA Nephropathy
Sites: Beijing, China
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT05505955 · 83 participants · Start Oct 8, 2022 · Primary completion Nov 3, 2023
Drug: HRS-5965; Placebo · For: Glomerulonephritis
Sites: Qingdao, China
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyPivotal-lookingCompleted
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06593938 · 76 participants · Start Oct 25, 2024 · Primary completion Jul 31, 2025
Drug: HRS-5965 capsule; Eculizumab Injection · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China; Tianjin, China
- Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody TreatmentPivotal-lookingCompleted
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06715943 · 39 participants · Start Jan 7, 2025 · Primary completion Jan 6, 2026
Drug: HRS-5965 capsule · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China · 2 sites in all
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07040787 · 36 participants · Start Jul 8, 2025 · Primary completion Aug 17, 2025
Drug: HRS-5965 Capsules; Clopidogrel and 1 more · For: Complement Mediated Glomerular Diseases; Hemolytic Anemia
Sites: Nanchang, China
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06684041 · 32 participants · Start Nov 9, 2024 · Primary completion Apr 7, 2025
Drug: HRS-5965 capsule; HRS-5965 capsule placebo · For: Hemolytic Anemia
Sites: Wuhan, China
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06051357 · 26 participants · Start Nov 15, 2023 · Primary completion Mar 25, 2024
Drug: HRS-5965 tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial.
Xu Y, Tian F, Ren H, et al. · Med 2025
- Efficacy and safety of HRS-5965 monotherapy in complement inhibitor-naïve patients with paroxysmal nocturnal haemoglobinuria.
Zhang L, Liu Z, Zhao X, et al. · Br J Haematol 2025
Also in development for Primary IgA Nephropathy
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- SefaxersenRO7434656Phase 31 trial
Roche (Genentech) · Primary IgA Nephropathy
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.